Cellceutix Corp (CTIX) 1.5550 $CTIX
Cellceutix Successfully Completes In Vitro Study in Support of Planned Phase 2 Trial of Kevetrin for Ovarian Cancer
Marketwired - Thu Mar 31, 8:02AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce that the latest laboratory research on the Company's anti-cancer drug Kevetrin showed that Kevetrin did not inhibit or induce cytochrome P450 enzymes in vitro. Based upon the documented relationship of P450 and certain potential drug-drug interactions, this positive data is central to the planned Phase 2 clinical trial where Kevetrin will be used in a combination therapy for the treatment of ovarian cancer.
Cellceutix Receives Preliminary Approval for Clinical Trial of Brilacidin for Ulcerative Proctitis
Marketwired - Wed Mar 30, 9:01AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce that the Company has received initial approval for the planned Proof of Concept, Phase 2, clinical trial of Brilacidin for ulcerative proctitis.
Anthrax Market Pipeline Global Review Research Report for H2 2015
PR Newswire - Thu Mar 17, 9:00PM CDT
The "Anthrax - Pipeline Review, H2 2015" market research report provides an overview of the Anthrax's therapeutic pipeline and helps enhance decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
DVAX: 19.24 (+1.19), TTPH: 4.63 (+0.25), ADRO: 12.81 (+0.69), EBS: 36.35 (+1.13), UTHR: 111.43 (+1.49), BMY: 63.88 (+0.44), PFNX: 9.83 (+0.90), PIP: 1.89 (-0.08), IBIO: 0.57 (+0.01), OGEN: 0.90 (unch)
Cellceutix Concludes Last Patient Visit in Phase 2 FDA Trial of Oral Dosed Prurisol in Patients With Mild-to-Moderate Chronic Plaque Psoriasis
Marketwired - Thu Mar 17, 9:01AM CDT
Cellceutix (OTC: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce the conclusion of the last patient visit in its randomized, double-blind Phase 2 trial of orally-administered Prurisol for the treatment of mild to moderate chronic plaque psoriasis. The unblinding of the study and top-line data is expected to be available in May. Although the data is still blinded, there were no safety items of concern.
CELGZ: 1.31 (+0.11)
Technical Insights on Equity Movements -- Research Reports on ALUF Holdings, Vantage Drilling, Cellceutix and Yahoo Japan
ACCESSWIRE - Wed Mar 09, 6:30AM CST
NEW YORK, NY / ACCESSWIRE / March 9, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: ALUF Holdings Inc. (OTC: AHIX), Vantage Drilling Co. (OTC: VTGDF), Cellceutix Corp. (OTC: CTIX) and Yahoo Japan Corp. (OTC: YAHOY). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
Cellceutix Corporation Welcomes Dr. Stephen T. Sonis to Its Scientific Advisory Board
Marketwired - Tue Mar 08, 12:23PM CST
Cellceutix Corporation (OTC: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce that Dr. Stephen T. Sonis, D.M.D., D.M.Sc., has joined the Cellceutix Scientific Advisory Board. Dr. Sonis is one of the world's foremost experts in the research and clinical treatment of cancer-related oral mucosal toxicities. He currently holds appointments at the Harvard School of Dental Medicine as Professor of Oral Medicine (part-time), and is a Senior Surgeon at the Dana-Farber Cancer Institute and Brigham and Women's Hospital .
Endometrial Cancer Pipeline Market Research H2 2015 Report
PR Newswire - Wed Mar 02, 8:00PM CST
A market research report titled "Endometrial Cancer - Pipeline Review, H2 2015" provides an overview of the Endometrial Cancer's therapeutic pipeline and enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
INCY: 72.47 (+4.12), IMGN: 8.52 (+0.26), ARQL: 1.60 (+0.02), LLY: 72.01 (+0.23), GSK: 40.55 (-0.15), ONTY: 1.27 (+0.10), MDVN: 45.98 (+8.59), MRK: 52.91 (-0.31), AZN: 28.16 (-0.16), AVEO: 0.92 (-0.02), GALE: 1.36 (-0.02), PBYI: 29.37 (+1.84), NVS: 72.44 (-0.11), KPTI: 8.92 (+0.28), XLRN: 26.39 (+0.69), EXEL: 4.00 (+0.10)
Cellceutix Meets With FDA for Phase 2 Clinical Trial of Kevetrin for Ovarian Cancer
Marketwired - Wed Feb 10, 1:23PM CST
Cellceutix Corporation (OTC: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce that Cellceutix executives met this week with staff of the FDA Division of Oncology Products 1 to discuss the Kevetrin Phase 1 study data, as well as a proposed design of a planned Phase 2 trial in patients with ovarian cancer that have resistance to platinum-based therapy.
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H2 2015 - 78 Companies & Drug Profiles
M2 - Tue Feb 09, 10:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/ctt3q8/methicillinresist) has announced the addition of the "Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infectionsand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Methicillin-Resistant Staphylococcus Aureus (MRSA) InfectionsOverview - Therapeutics Development - Pipeline Products for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Overview - Pipeline Products for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Comparative Analysis - Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Therapeutics under Development by Companies - Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Therapeutics under Investigation by Universities/Institutes - Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Products under Development by Companies - Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Products under Investigation by Universities/Institutes - Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Companies Involved in Therapeutics Development Companies Mentioned - Absynth Biologics Limited - Adenium Biotech ApS - AIMM Therapeutics B.V. - Alchemia Limited - Allergan Plc - AlphaMab Co., Ltd - Alvogen Korea - AmpliPhi Biosciences Corporation - AnGes MG, Inc. - Aphios Corporation - AstraZeneca Plc - Aurigene Discovery Technologies Limited - Bharat Biotech International Limited - BioDiem Ltd - BioSource Pharm, Inc. - C3 Jian, Inc - Cellceutix Corporation - Cempra, Inc. - ContraFect Corporation - CrystalGenomics, Inc. - CSA Biotechnologies LLC - Debiopharm International S.A. - DesignMedix, Inc. - Destiny Pharma Limited - Dong-A Socio Group - Ensol Biosciences Inc. - Excelimmune, Inc. - Galapagos NV - GangaGen Inc. - Helix BioMedix, Inc. - Hsiri Therapeutics, LLC - Ildong Pharmaceutical Co., Ltd. - Immupharma Plc - ImmuVen, Inc. - iNtRON Biotechnology Inc. For more information visit http://www.researchandmarkets.com/research/ct...llinresist
AGN: 268.03 (-6.91), AZN: 28.16 (-0.16), CEMP: 17.52 (+1.24), APHB: 3.94 (-0.26), GLPG: 41.82 (-0.51)
Global Hypertension Pipeline Review 2015
M2 - Tue Feb 09, 10:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/vln7pk/hypertension) has announced the addition of the "Hypertension - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypertensionand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - HypertensionOverview - Therapeutics Development - Pipeline Products for Hypertension - Overview - Pipeline Products for Hypertension - Comparative Analysis - Hypertension - Therapeutics under Development by Companies - Hypertension - Therapeutics under Investigation by Universities/Institutes - Hypertension - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Hypertension - Products under Development by Companies - Hypertension - Products under Investigation by Universities/Institutes - Hypertension - Companies Involved in Therapeutics Development - A1M Pharma AB - AbbVie Inc. - Ache Laboratorios Farmaceuticos S/A - Actelion Ltd - Carolus Therapeutics, Inc. - Cellceutix Corporation - DiaMedica Inc. - Hanmi Pharmaceuticals, Co. Ltd. - Innopharmax Inc. - Insmed Incorporated - IntelGenx Corp. - Intercept Pharmaceuticals, Inc. - Ionis Pharmaceuticals, Inc. - Jeil Pharmaceutical Co., Ltd. - Jiangsu Hansoh Pharmaceutical Co., Ltd. - Jiangsu Hengrui Medicine Co., Ltd. - JW Pharmaceutical Corporation - Kowa Company, Ltd. - Lacer, S.A. - Nippon Kayaku Co., Ltd. - Nippon Shinyaku Co., Ltd. - Novartis AG - Noxamet Ltd - Omeros Corporation - Ono Pharmaceutical Co., Ltd. - Peloton Therapeutics, Inc. - Pfizer Inc. - Sihuan Pharmaceutical Holdings Group Ltd. - Silence Therapeutics Plc - VBS Pharmaceuticals - Vectura Group Plc - VG Life Sciences, Inc. - Vicore Pharma AB - Yuhan Corporation For more information visit http://www.researchandmarkets.com/research/vl...pertension
INSM: 12.67 (+0.35), PFE: 29.64 (-0.43), OMER: 15.34 (+0.07), ICPT: 128.47 (+3.45), ABBV: 57.12 (+0.12), IONS: 40.50 (+1.87), NVS: 72.44 (-0.11)
Psoriasis Therapeutics Pipeline Review, H2 2015
M2 - Tue Feb 09, 8:28AM CST
Research and Markets (http://www.researchandmarkets.com/research/6tv9lw/psoriasis) has announced the addition of the "Psoriasis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Psoriasisand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - PsoriasisOverview - Therapeutics Development - Pipeline Products for Psoriasis- Overview - Pipeline Products for Psoriasis- Comparative Analysis - Psoriasis- Therapeutics under Development by Companies - Psoriasis- Therapeutics under Investigation by Universities/Institutes - Psoriasis- Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Psoriasis- Products under Development by Companies - Psoriasis- Products under Investigation by Universities/Institutes - Psoriasis- Companies Involved in Therapeutics Development Companies Mentioned - Sample List - 3SBio Inc. - 4SC AG - Abeome Corporation - AbGenomics International, Inc. - ADC Therapeutics Sarl - Addex Therapeutics Ltd - Advinus Therapeutics Ltd. - Ajinomoto Pharmaceuticals Co., Ltd. - AlbireoPharma - Allozyne, Inc. - Almirall, S.A. - Amgen Inc. - Anacor Pharmaceuticals, Inc. - AnaptysBio, Inc. - Arena Pharmaceuticals, Inc. - Argos Therapeutics, Inc. - Arrien Pharmaceuticals, LLC - AstraZeneca Plc - Athenex, Inc. - Aurigene Discovery Technologies Limited - Avesthagen Limited - Avexxin AS - Basilea Pharmaceutica AG - BIOCAD - Biocon Limited - BioLingus AG - BioMAS Ltd. - Bionomics Limited - Bionovis SA - Boehringer Ingelheim GmbH - Brickell Biotech, Inc. - Bristol-Myers Squibb Company - Can-Fite BioPharma Ltd. - Celgene Corporation - Cellceutix Corporation For more information visit http://www.researchandmarkets.com/research/6tv9lw/psoriasis
AMGN: 149.93 (+0.45), BMY: 63.88 (+0.44), CANF: 2.79 (+0.08), ARGS: 6.40 (-1.49), AZN: 28.16 (-0.16), ANAC: 53.45 (-5.21), ARNA: 1.97 (+0.06), CELGZ: 1.31 (+0.11)
Cellceutix to Submit Special Protocol Assessment Request to FDA for Phase 3 Clinical Study of Antibiotic Brilacidin for ABSSSI
Marketwired - Tue Feb 09, 8:25AM CST
Cellceutix Corporation (OTC: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce that it will be submitting a Special Protocol Assessment (SPA) request for phase 3 clinical research of its novel single-dose antibiotic, Brilacidin, for the treatment of Acute Bacterial Skin and Skin Structure Infection (ABSSSI) caused by Gram-positive bacteria. The Company anticipates submission of the SPA request to the U.S. Food and Drug Administration (FDA) within two weeks.
Head And Neck Cancer Therapeutics Pipeline Review, H2 2015
M2 - Tue Feb 09, 6:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/bls9lh/head_and_neck) has announced the addition of the "Head And Neck Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Head And Neck Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Head And Neck Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Head And Neck Cancer Overview - Therapeutics Development - Pipeline Products for Head And Neck Cancer - Overview - Pipeline Products for Head And Neck Cancer - Comparative Analysis - Head And Neck Cancer - Therapeutics under Development by Companies - Head And Neck Cancer - Therapeutics under Investigation by Universities/Institutes - Head And Neck Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Head And Neck Cancer - Products under Development by Companies - Head And Neck Cancer - Products under Investigation by Universities/Institutes - Head And Neck Cancer - Companies Involved in Therapeutics Development - 4SC AG - AB Science SA - AbbVie Inc. - Acceleron Pharma, Inc. - Advaxis, Inc. - Alchemia Limited - Altor BioScience Corporation - Ambrx, Inc. - Amgen Inc. - ANP Technologies, Inc. - arGEN-X BV - ArQule, Inc. - Ascenta Therapeutics, Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - ATLAB Pharma SAS - AVEO Pharmaceuticals, Inc. - Bayer AG - Bexion Pharmaceuticals, LLC. - BIND Therapeutics, Inc. - Bio-Path Holdings, Inc. - BioDiem Ltd - Bionovis SA - Biotest AG - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - CEL-SCI Corporation - Celgene Corporation - Cell Medica Limited - Cellceutix Corporation - Celldex Therapeutics, Inc. - Celltrion, Inc. - Centrose LLC - Cristal Therapeutics - Critical Outcome Technologies Inc. - CTI BioPharma Corp. - CytomX Therapeutics, Inc. - Daiichi Sankyo Company, Limited - EcoBiotics Limited For more information visit http://www.researchandmarkets.com/research/bl...d_and_neck
CVM: 0.53 (unch), AMBX: (), CLDX: 3.78 (+0.18), ARQL: 1.60 (+0.02), CTIC: 0.53 (+0.01), CTMX: 12.90 (+0.19), ABBV: 57.12 (+0.12), XLRN: 26.39 (+0.69), ADXS: 9.03 (+0.39), AMGN: 149.93 (+0.45), BIND: 2.20 (-0.01), BMY: 63.88 (+0.44), BPTH: 2.59 (+0.16), AZN: 28.16 (-0.16), AVEO: 0.92 (-0.02), CELGZ: 1.31 (+0.11)
Tuberculosis Therapeutics Development Pipeline Review, H2 2015 Featuring 60 Key Companies
M2 - Fri Feb 05, 4:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/b2fbvp/tuberculosis) has announced the addition of the "Tuberculosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Tuberculosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tuberculosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Tuberculosis Overview - Therapeutics Development - Pipeline Products for Tuberculosis - Overview - Pipeline Products for Tuberculosis - Comparative Analysis - Tuberculosis - Therapeutics under Development by Companies - Tuberculosis - Therapeutics under Investigation by Universities/Institutes - Tuberculosis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Tuberculosis - Products under Development by Companies - Tuberculosis - Products under Investigation by Universities/Institutes - Tuberculosis - Companies Involved in Therapeutics Development - Abera Bioscience AB - Achillion Pharmaceuticals, Inc. - BioDiem Ltd - BioLingus AG - Biomar Microbial Technologies - Bioversys AG - Celgene Corporation - Cellceutix Corporation - Chongqing Zhifei Biological Products Co., Ltd. - Ensol Biosciences Inc. - EpiVax, Inc. - FIT Biotech Oy - GangaGen Inc. - GlaxoSmithKline Plc - Globeimmune, Inc. - Hsiri Therapeutics, LLC - Imaxio SA - Immunitor, Inc. - ImmunoBiology Limited - Immunovaccine, Inc. - Inovio Pharmaceuticals, Inc. - Johnson & Johnson - Lipotek Pty Ltd. - Microbion Corporation - Microbiotix, Inc. - NEARMEDIC PLUS, Ltd - Novartis AG - Okklo Life Sciences BV - Orchid Chemicals & Pharmaceuticals Ltd - Otsuka Holdings Co., Ltd. - Polymun Scientific Immunbiologische Forschung GmbH - Prokarium Limited - QureTech Bio AB - Sanofi - Vichem Chemie Research Ltd. For more information visit http://www.researchandmarkets.com/research/b2...berculosis
JNJ: 108.20 (-0.78), INO: 8.71 (+0.08), ACHN: 7.72 (+0.20), GSK: 40.55 (-0.15), NVS: 72.44 (-0.11), CELGZ: 1.31 (+0.11)
World Thymus Cancer Pipeline Review, H2 2015
M2 - Thu Feb 04, 5:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/chmdh8/thymus_cancer) has announced the addition of the "Thymus Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Thymus Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thymus Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Thymus Cancer Overview - Therapeutics Development - Pipeline Products for Thymus Cancer - Overview - Pipeline Products for Thymus Cancer - Comparative Analysis - Thymus Cancer - Therapeutics under Development by Companies - Thymus Cancer - Therapeutics under Investigation by Universities/Institutes - Thymus Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Thymus Cancer - Products under Development by Companies - Thymus Cancer - Products under Investigation by Universities/Institutes - Thymus Cancer - Companies Involved in Therapeutics Development - Cellceutix Corporation - Merck & Co., Inc. - Novartis AG - Onxeo SA - Sumitomo Dainippon Pharma Co., Ltd. - Tiziana Life Sciences Plc For more information visit http://www.researchandmarkets.com/research/ch...mus_cancer
MRK: 52.91 (-0.31), NVS: 72.44 (-0.11)
Head And Neck Cancer Squamous Cell Carcinoma Pipeline Review, H2 2015
M2 - Thu Feb 04, 4:51AM CST
Research and Markets (http://www.researchandmarkets.com/research/3rtb7q/head_and_neck) has announced the addition of the "Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Head And Neck Cancer Squamous Cell Carcinoma Overview - Therapeutics Development - Pipeline Products for Head And Neck Cancer Squamous Cell Carcinoma - Overview - Pipeline Products for Head And Neck Cancer Squamous Cell Carcinoma - Comparative Analysis - Head And Neck Cancer Squamous Cell Carcinoma - Therapeutics under Development by Companies - Head And Neck Cancer Squamous Cell Carcinoma - Therapeutics under Investigation by Universities/Institutes - Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Head And Neck Cancer Squamous Cell Carcinoma - Products under Development by Companies - Head And Neck Cancer Squamous Cell Carcinoma - Products under Investigation by Universities/Institutes - Head And Neck Cancer Squamous Cell Carcinoma - Companies Involved in Therapeutics Development Companies Mentioned - Partial List - AB Science SA - AbbVie Inc. - Acceleron Pharma, Inc. - Altor BioScience Corporation - Amgen Inc. - Ascenta Therapeutics, Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - BIND Therapeutics, Inc. - Bionovis SA - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - CEL-SCI Corporation - Cellceutix Corporation - Celldex Therapeutics, Inc. - Celltrion, Inc. - Centrose LLC - Critical Outcome Technologies Inc. - Daiichi Sankyo Company, Limited - Eisai Co., Ltd. - Eli Lilly and Company - Etubics Corporation - F. Hoffmann-La Roche Ltd. - G&E Herbal Biotechnology Co., Ltd. - Genentech, Inc. - Genexine, Inc. - Genzyme Corporation - GlaxoSmithKline Plc - Gliknik, Inc. - Glycotope GmbH - Hanmi Pharmaceuticals, Co. Ltd. - ImmunoGen, Inc. - Immunomedics, Inc. - Immunovative Therapies, Ltd. For more information visit http://www.researchandmarkets.com/research/3r...d_and_neck About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
IMMU: 2.50 (-0.01), CVM: 0.53 (unch), CLDX: 3.78 (+0.18), IMGN: 8.52 (+0.26), AMGN: 149.93 (+0.45), LLY: 72.01 (+0.23), BIND: 2.20 (-0.01), GSK: 40.55 (-0.15), BMY: 63.88 (+0.44), AZN: 28.16 (-0.16), AVEO: 0.92 (-0.02), ABBV: 57.12 (+0.12), XLRN: 26.39 (+0.69)
Renal Cell Carcinoma Pipeline Review, H2 2015
M2 - Wed Feb 03, 10:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/5fx7fr/renal_cell) has announced the addition of the "Renal Cell Carcinoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Renal Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Renal Cell Carcinoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Renal Cell Carcinoma Overview - Therapeutics Development - Pipeline Products for Renal Cell Carcinoma - Overview - Pipeline Products for Renal Cell Carcinoma - Comparative Analysis - Renal Cell Carcinoma - Therapeutics under Development by Companies - Renal Cell Carcinoma - Therapeutics under Investigation by Universities/Institutes - Renal Cell Carcinoma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Renal Cell Carcinoma - Products under Development by Companies - Renal Cell Carcinoma - Products under Investigation by Universities/Institutes - Renal Cell Carcinoma - Companies Involved in Therapeutics Development Companies Featured (Partial List) - AbbVie Inc. - Acceleron Pharma, Inc. - Advenchen Laboratories, LLC - Altor BioScience Corporation - Ambrx, Inc. - Amgen Inc. - Ampio Pharmaceuticals, Inc. - arGEN-X BV - Argos Therapeutics, Inc. - Arrowhead Research Corporation - Astellas Pharma Inc. - Bayer AG - Beta Pharma, Inc. - Bio-Cancer Treatment International Limited - Bionomics Limited - Bionovis SA - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - Caladrius Biosciences, Inc. - Calithera Biosciences, Inc. - Cellceutix Corporation - Celldex Therapeutics, Inc. - Celltrion, Inc. - Cerulean Pharma, Inc. - Chipscreen Biosciences Ltd - Cytune Pharma SAS - Dr. Reddy's Laboratories Limited - EirGenix Inc. - Eisai Co., Ltd. - Eli Lilly and Company For more information visit http://www.researchandmarkets.com/research/5fx7fr/renal_cell
ARWR: 4.82 (+0.08), CERU: 2.71 (+0.04), AMBX: (), CLDX: 3.78 (+0.18), AMGN: 149.93 (+0.45), LLY: 72.01 (+0.23), AMPE: 2.25 (-0.01), BMY: 63.88 (+0.44), CLBS: 0.75 (-0.04), ARGS: 6.40 (-1.49), CALA: 5.68 (+0.08), ABBV: 57.12 (+0.12), XLRN: 26.39 (+0.69)
World Malaria Pipeline Review, H2 2015
M2 - Wed Feb 03, 10:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/wh66xl/malaria) has announced the addition of the "Malaria - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Malaria, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malaria and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Malaria Overview - Therapeutics Development - Pipeline Products for Malaria - Overview - Pipeline Products for Malaria - Comparative Analysis - Malaria - Therapeutics under Development by Companies - Malaria - Therapeutics under Investigation by Universities/Institutes - Malaria - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Malaria - Products under Development by Companies - Malaria - Products under Investigation by Universities/Institutes - Malaria - Companies Involved in Therapeutics Development - Partial List - 4SC AG - Acetylon Pharmaceuticals, Inc. - Actelion Ltd - Agilvax, Inc. - Akshaya Bio Inc. - Amura Holdings Limited - Artificial Cell Technologies, Inc. - AstraZeneca Plc - Bharat Biotech International Limited - Callaghan Innovation Research Ltd. - Carna Biosciences, Inc. - CEL-SCI Corporation - Celgene Corporation - Cellceutix Corporation - Chong Kun Dang Pharmaceutical Corp. - Cilian AG - Clevexel Pharma SAS - Daiichi Sankyo Company, Limited - DesignMedix, Inc. - Eisai Co., Ltd. - Folia Biotech Inc. - Genocea Biosciences, Inc. - GenVec, Inc. - Genzyme Corporation - GlaxoSmithKline Plc - iBio, Inc. - Imaxio SA - Immtech Pharmaceuticals, Inc. - Immunitor, Inc. - Inovio Pharmaceuticals, Inc. - IPCA Laboratories Limited - iQur Limited - IRBM Science Park SpA - Jenrin Discovery, Inc. - Jomaa Pharma GmbH For more information visit http://www.researchandmarkets.com/research/wh66xl/malaria
CVM: 0.53 (unch), GNCA: 7.74 (+3.77), GSK: 40.55 (-0.15), INO: 8.71 (+0.08), AZN: 28.16 (-0.16), IBIO: 0.57 (+0.01), CELGZ: 1.31 (+0.11)
What are Investors Looking at - Research on American Green, Sunshine Biopharma, Portlogic Systems and Cellceutix
ACCESSWIRE - Tue Feb 02, 6:40AM CST
NEW YORK, NY / ACCESSWIRE / February 2, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: American Green Inc. (OTC: ERBB), Sunshine Biopharma Inc. (OTC: SBFM), Portlogic Systems Inc. (OTC: PGSY) and Cellceutix Corp. (OTC: CTIX). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
Klebsiella Pneumoniae Infections Therapeutics Development Pipeline Review, H2 2015
M2 - Tue Feb 02, 6:39AM CST
Research and Markets (http://www.researchandmarkets.com/research/xdwshp/klebsiella) has announced the addition of the "Klebsiella Pneumoniae Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Klebsiella Pneumoniae Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Klebsiella Pneumoniae Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Klebsiella Pneumoniae Infections Overview - Therapeutics Development - Pipeline Products for Klebsiella Pneumoniae Infections - Overview - Pipeline Products for Klebsiella Pneumoniae Infections - Comparative Analysis - Klebsiella Pneumoniae Infections - Therapeutics under Development by Companies - Klebsiella Pneumoniae Infections - Therapeutics under Investigation by Universities/Institutes - Klebsiella Pneumoniae Infections - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Klebsiella Pneumoniae Infections - Products under Development by Companies - Klebsiella Pneumoniae Infections - Products under Investigation by Universities/Institutes - Klebsiella Pneumoniae Infections - Companies Involved in Therapeutics Development - Arsanis Biosciences GmbH - Boehringer Ingelheim GmbH - Cellceutix Corporation - Debiopharm International S.A. - Evaxion Biotech - F. Hoffmann-La Roche Ltd. - FOB Synthesis, Inc. - Melinta Therapeutics, Inc - Merck & Co., Inc. - MicuRx Pharmaceuticals, Inc. - Nosopharm SAS - Novan, Inc. - Pfizer Inc. - Phico Therapeutics Limited - Procarta Biosystems Ltd - Sarepta Therapeutics, Inc. - Shionogi & Co., Ltd. - Soligenix, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - Syntiron LLC - Tetraphase Pharmaceuticals Inc. - Theraclone Sciences, Inc. - Trana Discovery, Inc. For more information visit http://www.researchandmarkets.com/research/xdwshp/klebsiella
TTPH: 4.63 (+0.25), SRPT: 19.52 (+0.25), PFE: 29.64 (-0.43), MRK: 52.91 (-0.31)
Cellceutix Successfully Completes In Vitro Study in Support of Planned Phase 2 Trial of Kevetrin for Ovarian Cancer
Marketwired - Thu Mar 31, 8:02AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce that the latest laboratory research on the Company's anti-cancer drug Kevetrin showed that Kevetrin did not inhibit or induce cytochrome P450 enzymes in vitro. Based upon the documented relationship of P450 and certain potential drug-drug interactions, this positive data is central to the planned Phase 2 clinical trial where Kevetrin will be used in a combination therapy for the treatment of ovarian cancer. Cellceutix Receives Preliminary Approval for Clinical Trial of Brilacidin for Ulcerative Proctitis
Marketwired - Wed Mar 30, 9:01AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce that the Company has received initial approval for the planned Proof of Concept, Phase 2, clinical trial of Brilacidin for ulcerative proctitis. Anthrax Market Pipeline Global Review Research Report for H2 2015
PR Newswire - Thu Mar 17, 9:00PM CDT
The "Anthrax - Pipeline Review, H2 2015" market research report provides an overview of the Anthrax's therapeutic pipeline and helps enhance decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
DVAX: 19.24 (+1.19), TTPH: 4.63 (+0.25), ADRO: 12.81 (+0.69), EBS: 36.35 (+1.13), UTHR: 111.43 (+1.49), BMY: 63.88 (+0.44), PFNX: 9.83 (+0.90), PIP: 1.89 (-0.08), IBIO: 0.57 (+0.01), OGEN: 0.90 (unch)
Cellceutix Concludes Last Patient Visit in Phase 2 FDA Trial of Oral Dosed Prurisol in Patients With Mild-to-Moderate Chronic Plaque Psoriasis
Marketwired - Thu Mar 17, 9:01AM CDT
Cellceutix (OTC: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce the conclusion of the last patient visit in its randomized, double-blind Phase 2 trial of orally-administered Prurisol for the treatment of mild to moderate chronic plaque psoriasis. The unblinding of the study and top-line data is expected to be available in May. Although the data is still blinded, there were no safety items of concern. CELGZ: 1.31 (+0.11)
Technical Insights on Equity Movements -- Research Reports on ALUF Holdings, Vantage Drilling, Cellceutix and Yahoo Japan
ACCESSWIRE - Wed Mar 09, 6:30AM CST
NEW YORK, NY / ACCESSWIRE / March 9, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: ALUF Holdings Inc. (OTC: AHIX), Vantage Drilling Co. (OTC: VTGDF), Cellceutix Corp. (OTC: CTIX) and Yahoo Japan Corp. (OTC: YAHOY). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
Cellceutix Corporation Welcomes Dr. Stephen T. Sonis to Its Scientific Advisory Board
Marketwired - Tue Mar 08, 12:23PM CST
Cellceutix Corporation (OTC: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce that Dr. Stephen T. Sonis, D.M.D., D.M.Sc., has joined the Cellceutix Scientific Advisory Board. Dr. Sonis is one of the world's foremost experts in the research and clinical treatment of cancer-related oral mucosal toxicities. He currently holds appointments at the Harvard School of Dental Medicine as Professor of Oral Medicine (part-time), and is a Senior Surgeon at the Dana-Farber Cancer Institute and Brigham and Women's Hospital . Endometrial Cancer Pipeline Market Research H2 2015 Report
PR Newswire - Wed Mar 02, 8:00PM CST
A market research report titled "Endometrial Cancer - Pipeline Review, H2 2015" provides an overview of the Endometrial Cancer's therapeutic pipeline and enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
INCY: 72.47 (+4.12), IMGN: 8.52 (+0.26), ARQL: 1.60 (+0.02), LLY: 72.01 (+0.23), GSK: 40.55 (-0.15), ONTY: 1.27 (+0.10), MDVN: 45.98 (+8.59), MRK: 52.91 (-0.31), AZN: 28.16 (-0.16), AVEO: 0.92 (-0.02), GALE: 1.36 (-0.02), PBYI: 29.37 (+1.84), NVS: 72.44 (-0.11), KPTI: 8.92 (+0.28), XLRN: 26.39 (+0.69), EXEL: 4.00 (+0.10)
Cellceutix Meets With FDA for Phase 2 Clinical Trial of Kevetrin for Ovarian Cancer
Marketwired - Wed Feb 10, 1:23PM CST
Cellceutix Corporation (OTC: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce that Cellceutix executives met this week with staff of the FDA Division of Oncology Products 1 to discuss the Kevetrin Phase 1 study data, as well as a proposed design of a planned Phase 2 trial in patients with ovarian cancer that have resistance to platinum-based therapy. Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H2 2015 - 78 Companies & Drug Profiles
M2 - Tue Feb 09, 10:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/ctt3q8/methicillinresist) has announced the addition of the "Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infectionsand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Methicillin-Resistant Staphylococcus Aureus (MRSA) InfectionsOverview - Therapeutics Development - Pipeline Products for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Overview - Pipeline Products for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Comparative Analysis - Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Therapeutics under Development by Companies - Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Therapeutics under Investigation by Universities/Institutes - Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Products under Development by Companies - Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Products under Investigation by Universities/Institutes - Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Companies Involved in Therapeutics Development Companies Mentioned - Absynth Biologics Limited - Adenium Biotech ApS - AIMM Therapeutics B.V. - Alchemia Limited - Allergan Plc - AlphaMab Co., Ltd - Alvogen Korea - AmpliPhi Biosciences Corporation - AnGes MG, Inc. - Aphios Corporation - AstraZeneca Plc - Aurigene Discovery Technologies Limited - Bharat Biotech International Limited - BioDiem Ltd - BioSource Pharm, Inc. - C3 Jian, Inc - Cellceutix Corporation - Cempra, Inc. - ContraFect Corporation - CrystalGenomics, Inc. - CSA Biotechnologies LLC - Debiopharm International S.A. - DesignMedix, Inc. - Destiny Pharma Limited - Dong-A Socio Group - Ensol Biosciences Inc. - Excelimmune, Inc. - Galapagos NV - GangaGen Inc. - Helix BioMedix, Inc. - Hsiri Therapeutics, LLC - Ildong Pharmaceutical Co., Ltd. - Immupharma Plc - ImmuVen, Inc. - iNtRON Biotechnology Inc. For more information visit http://www.researchandmarkets.com/research/ct...llinresist
AGN: 268.03 (-6.91), AZN: 28.16 (-0.16), CEMP: 17.52 (+1.24), APHB: 3.94 (-0.26), GLPG: 41.82 (-0.51)
Global Hypertension Pipeline Review 2015
M2 - Tue Feb 09, 10:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/vln7pk/hypertension) has announced the addition of the "Hypertension - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypertensionand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - HypertensionOverview - Therapeutics Development - Pipeline Products for Hypertension - Overview - Pipeline Products for Hypertension - Comparative Analysis - Hypertension - Therapeutics under Development by Companies - Hypertension - Therapeutics under Investigation by Universities/Institutes - Hypertension - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Hypertension - Products under Development by Companies - Hypertension - Products under Investigation by Universities/Institutes - Hypertension - Companies Involved in Therapeutics Development - A1M Pharma AB - AbbVie Inc. - Ache Laboratorios Farmaceuticos S/A - Actelion Ltd - Carolus Therapeutics, Inc. - Cellceutix Corporation - DiaMedica Inc. - Hanmi Pharmaceuticals, Co. Ltd. - Innopharmax Inc. - Insmed Incorporated - IntelGenx Corp. - Intercept Pharmaceuticals, Inc. - Ionis Pharmaceuticals, Inc. - Jeil Pharmaceutical Co., Ltd. - Jiangsu Hansoh Pharmaceutical Co., Ltd. - Jiangsu Hengrui Medicine Co., Ltd. - JW Pharmaceutical Corporation - Kowa Company, Ltd. - Lacer, S.A. - Nippon Kayaku Co., Ltd. - Nippon Shinyaku Co., Ltd. - Novartis AG - Noxamet Ltd - Omeros Corporation - Ono Pharmaceutical Co., Ltd. - Peloton Therapeutics, Inc. - Pfizer Inc. - Sihuan Pharmaceutical Holdings Group Ltd. - Silence Therapeutics Plc - VBS Pharmaceuticals - Vectura Group Plc - VG Life Sciences, Inc. - Vicore Pharma AB - Yuhan Corporation For more information visit http://www.researchandmarkets.com/research/vl...pertension
INSM: 12.67 (+0.35), PFE: 29.64 (-0.43), OMER: 15.34 (+0.07), ICPT: 128.47 (+3.45), ABBV: 57.12 (+0.12), IONS: 40.50 (+1.87), NVS: 72.44 (-0.11)
Psoriasis Therapeutics Pipeline Review, H2 2015
M2 - Tue Feb 09, 8:28AM CST
Research and Markets (http://www.researchandmarkets.com/research/6tv9lw/psoriasis) has announced the addition of the "Psoriasis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Psoriasisand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - PsoriasisOverview - Therapeutics Development - Pipeline Products for Psoriasis- Overview - Pipeline Products for Psoriasis- Comparative Analysis - Psoriasis- Therapeutics under Development by Companies - Psoriasis- Therapeutics under Investigation by Universities/Institutes - Psoriasis- Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Psoriasis- Products under Development by Companies - Psoriasis- Products under Investigation by Universities/Institutes - Psoriasis- Companies Involved in Therapeutics Development Companies Mentioned - Sample List - 3SBio Inc. - 4SC AG - Abeome Corporation - AbGenomics International, Inc. - ADC Therapeutics Sarl - Addex Therapeutics Ltd - Advinus Therapeutics Ltd. - Ajinomoto Pharmaceuticals Co., Ltd. - AlbireoPharma - Allozyne, Inc. - Almirall, S.A. - Amgen Inc. - Anacor Pharmaceuticals, Inc. - AnaptysBio, Inc. - Arena Pharmaceuticals, Inc. - Argos Therapeutics, Inc. - Arrien Pharmaceuticals, LLC - AstraZeneca Plc - Athenex, Inc. - Aurigene Discovery Technologies Limited - Avesthagen Limited - Avexxin AS - Basilea Pharmaceutica AG - BIOCAD - Biocon Limited - BioLingus AG - BioMAS Ltd. - Bionomics Limited - Bionovis SA - Boehringer Ingelheim GmbH - Brickell Biotech, Inc. - Bristol-Myers Squibb Company - Can-Fite BioPharma Ltd. - Celgene Corporation - Cellceutix Corporation For more information visit http://www.researchandmarkets.com/research/6tv9lw/psoriasis
AMGN: 149.93 (+0.45), BMY: 63.88 (+0.44), CANF: 2.79 (+0.08), ARGS: 6.40 (-1.49), AZN: 28.16 (-0.16), ANAC: 53.45 (-5.21), ARNA: 1.97 (+0.06), CELGZ: 1.31 (+0.11)
Cellceutix to Submit Special Protocol Assessment Request to FDA for Phase 3 Clinical Study of Antibiotic Brilacidin for ABSSSI
Marketwired - Tue Feb 09, 8:25AM CST
Cellceutix Corporation (OTC: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce that it will be submitting a Special Protocol Assessment (SPA) request for phase 3 clinical research of its novel single-dose antibiotic, Brilacidin, for the treatment of Acute Bacterial Skin and Skin Structure Infection (ABSSSI) caused by Gram-positive bacteria. The Company anticipates submission of the SPA request to the U.S. Food and Drug Administration (FDA) within two weeks. Head And Neck Cancer Therapeutics Pipeline Review, H2 2015
M2 - Tue Feb 09, 6:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/bls9lh/head_and_neck) has announced the addition of the "Head And Neck Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Head And Neck Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Head And Neck Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Head And Neck Cancer Overview - Therapeutics Development - Pipeline Products for Head And Neck Cancer - Overview - Pipeline Products for Head And Neck Cancer - Comparative Analysis - Head And Neck Cancer - Therapeutics under Development by Companies - Head And Neck Cancer - Therapeutics under Investigation by Universities/Institutes - Head And Neck Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Head And Neck Cancer - Products under Development by Companies - Head And Neck Cancer - Products under Investigation by Universities/Institutes - Head And Neck Cancer - Companies Involved in Therapeutics Development - 4SC AG - AB Science SA - AbbVie Inc. - Acceleron Pharma, Inc. - Advaxis, Inc. - Alchemia Limited - Altor BioScience Corporation - Ambrx, Inc. - Amgen Inc. - ANP Technologies, Inc. - arGEN-X BV - ArQule, Inc. - Ascenta Therapeutics, Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - ATLAB Pharma SAS - AVEO Pharmaceuticals, Inc. - Bayer AG - Bexion Pharmaceuticals, LLC. - BIND Therapeutics, Inc. - Bio-Path Holdings, Inc. - BioDiem Ltd - Bionovis SA - Biotest AG - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - CEL-SCI Corporation - Celgene Corporation - Cell Medica Limited - Cellceutix Corporation - Celldex Therapeutics, Inc. - Celltrion, Inc. - Centrose LLC - Cristal Therapeutics - Critical Outcome Technologies Inc. - CTI BioPharma Corp. - CytomX Therapeutics, Inc. - Daiichi Sankyo Company, Limited - EcoBiotics Limited For more information visit http://www.researchandmarkets.com/research/bl...d_and_neck
CVM: 0.53 (unch), AMBX: (), CLDX: 3.78 (+0.18), ARQL: 1.60 (+0.02), CTIC: 0.53 (+0.01), CTMX: 12.90 (+0.19), ABBV: 57.12 (+0.12), XLRN: 26.39 (+0.69), ADXS: 9.03 (+0.39), AMGN: 149.93 (+0.45), BIND: 2.20 (-0.01), BMY: 63.88 (+0.44), BPTH: 2.59 (+0.16), AZN: 28.16 (-0.16), AVEO: 0.92 (-0.02), CELGZ: 1.31 (+0.11)
Tuberculosis Therapeutics Development Pipeline Review, H2 2015 Featuring 60 Key Companies
M2 - Fri Feb 05, 4:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/b2fbvp/tuberculosis) has announced the addition of the "Tuberculosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Tuberculosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tuberculosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Tuberculosis Overview - Therapeutics Development - Pipeline Products for Tuberculosis - Overview - Pipeline Products for Tuberculosis - Comparative Analysis - Tuberculosis - Therapeutics under Development by Companies - Tuberculosis - Therapeutics under Investigation by Universities/Institutes - Tuberculosis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Tuberculosis - Products under Development by Companies - Tuberculosis - Products under Investigation by Universities/Institutes - Tuberculosis - Companies Involved in Therapeutics Development - Abera Bioscience AB - Achillion Pharmaceuticals, Inc. - BioDiem Ltd - BioLingus AG - Biomar Microbial Technologies - Bioversys AG - Celgene Corporation - Cellceutix Corporation - Chongqing Zhifei Biological Products Co., Ltd. - Ensol Biosciences Inc. - EpiVax, Inc. - FIT Biotech Oy - GangaGen Inc. - GlaxoSmithKline Plc - Globeimmune, Inc. - Hsiri Therapeutics, LLC - Imaxio SA - Immunitor, Inc. - ImmunoBiology Limited - Immunovaccine, Inc. - Inovio Pharmaceuticals, Inc. - Johnson & Johnson - Lipotek Pty Ltd. - Microbion Corporation - Microbiotix, Inc. - NEARMEDIC PLUS, Ltd - Novartis AG - Okklo Life Sciences BV - Orchid Chemicals & Pharmaceuticals Ltd - Otsuka Holdings Co., Ltd. - Polymun Scientific Immunbiologische Forschung GmbH - Prokarium Limited - QureTech Bio AB - Sanofi - Vichem Chemie Research Ltd. For more information visit http://www.researchandmarkets.com/research/b2...berculosis
JNJ: 108.20 (-0.78), INO: 8.71 (+0.08), ACHN: 7.72 (+0.20), GSK: 40.55 (-0.15), NVS: 72.44 (-0.11), CELGZ: 1.31 (+0.11)
World Thymus Cancer Pipeline Review, H2 2015
M2 - Thu Feb 04, 5:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/chmdh8/thymus_cancer) has announced the addition of the "Thymus Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Thymus Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thymus Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Thymus Cancer Overview - Therapeutics Development - Pipeline Products for Thymus Cancer - Overview - Pipeline Products for Thymus Cancer - Comparative Analysis - Thymus Cancer - Therapeutics under Development by Companies - Thymus Cancer - Therapeutics under Investigation by Universities/Institutes - Thymus Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Thymus Cancer - Products under Development by Companies - Thymus Cancer - Products under Investigation by Universities/Institutes - Thymus Cancer - Companies Involved in Therapeutics Development - Cellceutix Corporation - Merck & Co., Inc. - Novartis AG - Onxeo SA - Sumitomo Dainippon Pharma Co., Ltd. - Tiziana Life Sciences Plc For more information visit http://www.researchandmarkets.com/research/ch...mus_cancer
MRK: 52.91 (-0.31), NVS: 72.44 (-0.11)
Head And Neck Cancer Squamous Cell Carcinoma Pipeline Review, H2 2015
M2 - Thu Feb 04, 4:51AM CST
Research and Markets (http://www.researchandmarkets.com/research/3rtb7q/head_and_neck) has announced the addition of the "Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Head And Neck Cancer Squamous Cell Carcinoma Overview - Therapeutics Development - Pipeline Products for Head And Neck Cancer Squamous Cell Carcinoma - Overview - Pipeline Products for Head And Neck Cancer Squamous Cell Carcinoma - Comparative Analysis - Head And Neck Cancer Squamous Cell Carcinoma - Therapeutics under Development by Companies - Head And Neck Cancer Squamous Cell Carcinoma - Therapeutics under Investigation by Universities/Institutes - Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Head And Neck Cancer Squamous Cell Carcinoma - Products under Development by Companies - Head And Neck Cancer Squamous Cell Carcinoma - Products under Investigation by Universities/Institutes - Head And Neck Cancer Squamous Cell Carcinoma - Companies Involved in Therapeutics Development Companies Mentioned - Partial List - AB Science SA - AbbVie Inc. - Acceleron Pharma, Inc. - Altor BioScience Corporation - Amgen Inc. - Ascenta Therapeutics, Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - BIND Therapeutics, Inc. - Bionovis SA - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - CEL-SCI Corporation - Cellceutix Corporation - Celldex Therapeutics, Inc. - Celltrion, Inc. - Centrose LLC - Critical Outcome Technologies Inc. - Daiichi Sankyo Company, Limited - Eisai Co., Ltd. - Eli Lilly and Company - Etubics Corporation - F. Hoffmann-La Roche Ltd. - G&E Herbal Biotechnology Co., Ltd. - Genentech, Inc. - Genexine, Inc. - Genzyme Corporation - GlaxoSmithKline Plc - Gliknik, Inc. - Glycotope GmbH - Hanmi Pharmaceuticals, Co. Ltd. - ImmunoGen, Inc. - Immunomedics, Inc. - Immunovative Therapies, Ltd. For more information visit http://www.researchandmarkets.com/research/3r...d_and_neck About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
IMMU: 2.50 (-0.01), CVM: 0.53 (unch), CLDX: 3.78 (+0.18), IMGN: 8.52 (+0.26), AMGN: 149.93 (+0.45), LLY: 72.01 (+0.23), BIND: 2.20 (-0.01), GSK: 40.55 (-0.15), BMY: 63.88 (+0.44), AZN: 28.16 (-0.16), AVEO: 0.92 (-0.02), ABBV: 57.12 (+0.12), XLRN: 26.39 (+0.69)
Renal Cell Carcinoma Pipeline Review, H2 2015
M2 - Wed Feb 03, 10:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/5fx7fr/renal_cell) has announced the addition of the "Renal Cell Carcinoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Renal Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Renal Cell Carcinoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Renal Cell Carcinoma Overview - Therapeutics Development - Pipeline Products for Renal Cell Carcinoma - Overview - Pipeline Products for Renal Cell Carcinoma - Comparative Analysis - Renal Cell Carcinoma - Therapeutics under Development by Companies - Renal Cell Carcinoma - Therapeutics under Investigation by Universities/Institutes - Renal Cell Carcinoma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Renal Cell Carcinoma - Products under Development by Companies - Renal Cell Carcinoma - Products under Investigation by Universities/Institutes - Renal Cell Carcinoma - Companies Involved in Therapeutics Development Companies Featured (Partial List) - AbbVie Inc. - Acceleron Pharma, Inc. - Advenchen Laboratories, LLC - Altor BioScience Corporation - Ambrx, Inc. - Amgen Inc. - Ampio Pharmaceuticals, Inc. - arGEN-X BV - Argos Therapeutics, Inc. - Arrowhead Research Corporation - Astellas Pharma Inc. - Bayer AG - Beta Pharma, Inc. - Bio-Cancer Treatment International Limited - Bionomics Limited - Bionovis SA - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - Caladrius Biosciences, Inc. - Calithera Biosciences, Inc. - Cellceutix Corporation - Celldex Therapeutics, Inc. - Celltrion, Inc. - Cerulean Pharma, Inc. - Chipscreen Biosciences Ltd - Cytune Pharma SAS - Dr. Reddy's Laboratories Limited - EirGenix Inc. - Eisai Co., Ltd. - Eli Lilly and Company For more information visit http://www.researchandmarkets.com/research/5fx7fr/renal_cell
ARWR: 4.82 (+0.08), CERU: 2.71 (+0.04), AMBX: (), CLDX: 3.78 (+0.18), AMGN: 149.93 (+0.45), LLY: 72.01 (+0.23), AMPE: 2.25 (-0.01), BMY: 63.88 (+0.44), CLBS: 0.75 (-0.04), ARGS: 6.40 (-1.49), CALA: 5.68 (+0.08), ABBV: 57.12 (+0.12), XLRN: 26.39 (+0.69)
World Malaria Pipeline Review, H2 2015
M2 - Wed Feb 03, 10:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/wh66xl/malaria) has announced the addition of the "Malaria - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Malaria, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malaria and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Malaria Overview - Therapeutics Development - Pipeline Products for Malaria - Overview - Pipeline Products for Malaria - Comparative Analysis - Malaria - Therapeutics under Development by Companies - Malaria - Therapeutics under Investigation by Universities/Institutes - Malaria - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Malaria - Products under Development by Companies - Malaria - Products under Investigation by Universities/Institutes - Malaria - Companies Involved in Therapeutics Development - Partial List - 4SC AG - Acetylon Pharmaceuticals, Inc. - Actelion Ltd - Agilvax, Inc. - Akshaya Bio Inc. - Amura Holdings Limited - Artificial Cell Technologies, Inc. - AstraZeneca Plc - Bharat Biotech International Limited - Callaghan Innovation Research Ltd. - Carna Biosciences, Inc. - CEL-SCI Corporation - Celgene Corporation - Cellceutix Corporation - Chong Kun Dang Pharmaceutical Corp. - Cilian AG - Clevexel Pharma SAS - Daiichi Sankyo Company, Limited - DesignMedix, Inc. - Eisai Co., Ltd. - Folia Biotech Inc. - Genocea Biosciences, Inc. - GenVec, Inc. - Genzyme Corporation - GlaxoSmithKline Plc - iBio, Inc. - Imaxio SA - Immtech Pharmaceuticals, Inc. - Immunitor, Inc. - Inovio Pharmaceuticals, Inc. - IPCA Laboratories Limited - iQur Limited - IRBM Science Park SpA - Jenrin Discovery, Inc. - Jomaa Pharma GmbH For more information visit http://www.researchandmarkets.com/research/wh66xl/malaria
CVM: 0.53 (unch), GNCA: 7.74 (+3.77), GSK: 40.55 (-0.15), INO: 8.71 (+0.08), AZN: 28.16 (-0.16), IBIO: 0.57 (+0.01), CELGZ: 1.31 (+0.11)
What are Investors Looking at - Research on American Green, Sunshine Biopharma, Portlogic Systems and Cellceutix
ACCESSWIRE - Tue Feb 02, 6:40AM CST
NEW YORK, NY / ACCESSWIRE / February 2, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: American Green Inc. (OTC: ERBB), Sunshine Biopharma Inc. (OTC: SBFM), Portlogic Systems Inc. (OTC: PGSY) and Cellceutix Corp. (OTC: CTIX). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
Klebsiella Pneumoniae Infections Therapeutics Development Pipeline Review, H2 2015
M2 - Tue Feb 02, 6:39AM CST
Research and Markets (http://www.researchandmarkets.com/research/xdwshp/klebsiella) has announced the addition of the "Klebsiella Pneumoniae Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Klebsiella Pneumoniae Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Klebsiella Pneumoniae Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Klebsiella Pneumoniae Infections Overview - Therapeutics Development - Pipeline Products for Klebsiella Pneumoniae Infections - Overview - Pipeline Products for Klebsiella Pneumoniae Infections - Comparative Analysis - Klebsiella Pneumoniae Infections - Therapeutics under Development by Companies - Klebsiella Pneumoniae Infections - Therapeutics under Investigation by Universities/Institutes - Klebsiella Pneumoniae Infections - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Klebsiella Pneumoniae Infections - Products under Development by Companies - Klebsiella Pneumoniae Infections - Products under Investigation by Universities/Institutes - Klebsiella Pneumoniae Infections - Companies Involved in Therapeutics Development - Arsanis Biosciences GmbH - Boehringer Ingelheim GmbH - Cellceutix Corporation - Debiopharm International S.A. - Evaxion Biotech - F. Hoffmann-La Roche Ltd. - FOB Synthesis, Inc. - Melinta Therapeutics, Inc - Merck & Co., Inc. - MicuRx Pharmaceuticals, Inc. - Nosopharm SAS - Novan, Inc. - Pfizer Inc. - Phico Therapeutics Limited - Procarta Biosystems Ltd - Sarepta Therapeutics, Inc. - Shionogi & Co., Ltd. - Soligenix, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - Syntiron LLC - Tetraphase Pharmaceuticals Inc. - Theraclone Sciences, Inc. - Trana Discovery, Inc. For more information visit http://www.researchandmarkets.com/research/xdwshp/klebsiella
TTPH: 4.63 (+0.25), SRPT: 19.52 (+0.25), PFE: 29.64 (-0.43), MRK: 52.91 (-0.31)
